Shenhao started after the college entrance examination

Moia is not a founding member of Amgen Pharmaceuticals. She bought Amgen Pharmaceuticals' stock ten years ago at a price of only $55 per share, with a total cost of only $770 million.

Let's not talk about how much Moia has gained from Amgen Pharmaceuticals' dividends in the past ten years. If it is sold at a price of $3.85 billion now, it is equivalent to a direct income of $3.08 billion!

Although this income still needs to be taxed, is that a problem?

Moiya thought about it for a while and responded, "I am not satisfied with this price, Ms. Pollitt, you can also think about it again."

Clara immediately asked back, "What is the price in Ms. Martha's mind?"

Moiya was silent for a moment before adding, "In the case of over-the-counter transactions like ours, there is only a 10% premium, which I think is indeed very low."

"For example, the current rumored acquisition of Xilinx by AMD, according to rumors, the premium offered by AMD has reached 25%." Moiya gave an example.

"For example, the previous acquisition of Cypress by Infineon, the final negotiated price was a premium of more than 50%." Moiya gave a second higher premium example.

"Ms. Pollitt, I know you are definitely not acquiring our company's shares yourself." Moiya said with a smile.

Clara remained silent.

Moiya continued, "Although Ms. Pollitt is very famous in the investment community and is known as an independent investor with unique vision, the stocks in my hands are at least worth nearly $4 billion, and you can't take out the cash at all. "

This analysis is correct!

That's more than 3 billion, nearly 4 billion dollars in cash, how many people can take it out?

So Moiya directly guessed that it was not Clara who wanted to buy her stocks, and there must be someone else behind it.

Clara remained silent.

"Ms. Pollitt, if you want to buy my stocks, then show some sincerity. I don't expect you to pay a 50% premium. I only hope you will pay a 20% premium. At a price of $300 per share, I am willing to make the deal." Moiya directly gave the final price.

If calculated at a price of $300, the final acquisition price is $4.2 billion. Compared with the cost of $770 million, she can get $3.43 billion in pre-tax profits.

Clara did not respond immediately. She sighed and said, "Please wait a moment."

Moiya smiled. This answer meant that her guess was correct. Sure enough, there were other people behind this acquisition.

Clara immediately sent a message to Uriah, the senior vice president of investment at Pioneer Navigation Capital Group, explaining the current situation and then giving Moiya's speculation and the offer feedback.

Faced with a price of up to $300, Uriah hesitated for a moment and then agreed directly. (To read the novel, go to Faloo Novel Network!)

Although the current share price of Amgen Pharmaceuticals is less than $250 in the stock market, the share price is too mysterious. As long as the five major capital groups dare to acquire Amgen Pharmaceuticals' shares on a large scale in the stock market, the share price will definitely soar.

If you want to acquire 14 million shares of Amgen Pharmaceuticals from the stock market, I am afraid the final average price will only be higher.

If it is just spending money, it is still a small problem.

But they have already acquired more than 35 million shares of Amgen Pharmaceuticals, and now they have acquired 14 million shares of Amgen Pharmaceuticals on a large scale. It will be more difficult to acquire Amgen Pharmaceuticals' shares in the next step.

In order to avoid such a situation, Uriah still chose to accept the offer given by Moiya.

After Clara received Uriah's reply, she also replied to Moiya as soon as possible.

"Ms. Martha, we agree with your offer, but we hope to complete the transaction today." Clara stated her requirements.

Moiya raised her eyebrows slightly, and she secretly wondered whether to raise the price a little more?

After all, judging from Clara's performance, the other party was very anxious to acquire Amgen Pharmaceuticals' shares, as if they were very optimistic about Amgen Pharmaceuticals.

Moiya is the supervisor of Amgen Pharmaceuticals. She secretly wondered what research and development results Amgen Pharmaceuticals had recently achieved, otherwise why would anyone value Amgen Pharmaceuticals so much?

Clara looked at Moiya's hesitant expression, and she added directly, "If (Li Le's) Ms. Martha wants to increase the offer again, our discussion will be terminated directly."

"Amgen Pharmaceuticals is not the only shareholder of Ms. Martha." Clara added.

Moiya is only the first target selected by the five major capital groups through background investigation, not the only target. The five major capital groups want to obtain more shares of Amgen Pharmaceuticals, not just Moiya's less than 3% of shares.

So if Moiya really raises the offer again, the five major capital groups will definitely not continue to agree.

After all, if they continue to agree to Moiya's new offer, it means that they attach too much importance to Amgen Pharmaceuticals. Will Moiya raise the offer again? .